|
|
| | Myristoyl-L-carnitine-14,14,14-d3 (chloride) Basic information |
| | Myristoyl-L-carnitine-14,14,14-d3 (chloride) Chemical Properties |
| solubility | DMF: 20 mg/ml DMSO: 14 mg/ml Ethanol: 20 mg/ml |
| | Myristoyl-L-carnitine-14,14,14-d3 (chloride) Usage And Synthesis |
| Description | Myristoyl-L-carnitine-14,14,14-d3 is intended for use as an internal standard for the quantification of myristoyl-L-carnitine (Item No. 26559) by GC- or LC-MS. Myristoyl-L-carnitine is a naturally occurring long-chain acylcarnitine.1 Plasma levels of myristoyl-L-carnitine are decreased in patients with chronic fatigue syndrome and increased in patients with end-stage renal disease.1,2WARNING This product is not for human or veterinary use. | | References | [1] STEPHANIE E REUTER. Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease.[J]. Annals of Clinical Biochemistry, 2005, 42 Pt 5: 387-393. DOI: 10.1258/0004563054889954 [2] S. E. REUTER A. M E. Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity[J]. Journal of Internal Medicine, 2010, 270 1: 76-84. DOI: 10.1111/j.1365-2796.2010.02341.x |
| | Myristoyl-L-carnitine-14,14,14-d3 (chloride) Preparation Products And Raw materials |
|